Nonalcoholic fatty liver disease: Diagnostic biomarkers
|
摘要
Nonalcoholic fatty liver disease is a common medical condition worldwide and its prevalence has increased notably in the past few years due to the increases in prevalence of obesity and metabolic syndrome. However, diagnosis of this disease is still a matter of debate because of disease variations and pathophysiologic alterations. Specific single markers have gained con-siderable attention recently, among them markers related to hepatic pathophysiology, inflammation, adipocytokines and so forth. But, it seems that no single marker is sufficient for diagnosis and staging of the disease, and applying a panel including different types of tests may be more useful.
Nonalcoholic fatty liver disease is a common medical condition worldwide and its prevalence has increased notably in the past few years due to the increases in prevalence of obesity and metabolic syndrome. However, diagnosis of this disease is still a matter of debate because of disease variations and pathophysiologic alterations. Specific single markers have gained con-siderable attention recently, among them markers related to hepatic pathophysiology, inflammation, adipocytokines and so forth. But, it seems that no single marker is sufficient for diagnosis and staging of the disease, and applying a panel including different types of tests may be more useful.
Nonalcoholic fatty liver disease is a common medical condition worldwide and its prevalence has increased notably in the past few years due to the increases in prevalence of obesity and metabolic syndrome. However, diagnosis of this disease is still a matter of debate because of disease variations and pathophysiologic alterations. Specific single markers have gained con-siderable attention recently, among them markers related to hepatic pathophysiology, inflammation, adipocytokines and so forth. But, it seems that no single marker is sufficient for diagnosis and staging of the disease, and applying a panel including different types of tests may be more useful.
引文
1 Sumida Y,Yoshikawa T,Tanaka S,Taketani H,Kanemasa K,Nishimura T,Yamaguchi K,Mitsuyoshi H,Yasui K,Minami M,Naito Y,Itoh Y.The‘donations for decreased ALT(D4D)’prosocial behavior incentive scheme for NAFLD patients.J Public Health(Oxf)2014;36:629-634[PMID:24099735 DOI:10.1093/pubmed/fdt098]
2 Moore JB.Non-alcoholic fatty liver disease:the hepatic consequence of obesity and the metabolic syndrome.Proc Nutr Soc 2010;69:211-220[PMID:20158939 DOI:10.1017/S0029665110000030]
3 Paschos P,Paletas K.Non alcoholic fatty liver disease and metabolic syndrome.Hippokratia 2009;13:9-19[PMID:19240815]
4 Pulzi FB,Cisternas R,Melo MR,Ribeiro CM,Malheiros CA,Salles JE.New clinical score to diagnose nonalcoholic steatohepatitis in obese patients.Diabetol Metab Syndr 2011;3:3[PMID:21345221DOI:10.1186/1758-5996-3-3]
5 Collier J.Non-alcoholic fatty liver disease.Medicine 2007;35:86-88[DOI:10.1016/j.mpmed.2006.11.010]
6 Tevar AD,Clarke C,Wang J,Rudich SM,Woodle ES,Lentsch AB,Edwards ML.Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.J Am Coll Surg 2010;210:515-526[PMID:20347746 DOI:10.1016/j.jamcollsurg.2010.01.020]
7 Chitturi S,Farrell GC,Hashimoto E,Saibara T,Lau GK,Sollano JD.Non-alcoholic fatty liver disease in the Asia-Pacific region:definitions and overview of proposed guidelines.J Gastroenterol Hepatol 2007;22:778-787[PMID:17565630 DOI:10.1111/j.1440-1746.2007.05001.x]
8 Fan JG,Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China.J Hepatol 2009;50:204-210[PMID:19014878DOI:10.1016/j.jhep.2008.10.010]
9 Westerbacka J,Cornér A,Tiikkainen M,Tamminen M,Vehkavaara S,H?kkinen AM,Fredriksson J,Yki-J?rvinen H.Women and men have similar amounts of liver and intra-abdominal fat,despite more subcutaneous fat in women:implications for sex differences in markers of cardiovascular risk.Diabetologia 2004;47:1360-1369[PMID:15309287 DOI:10.1007/s00125-004-1460-1]
10 De Hewavisenthi SJ,Dassanayaka AS,De Silva HJ.Clinical,biochemical and histological characteristics of a Sri Lankan population of non-alcoholic steatohepatitis(NASH)patients.Ceylon Med J 2005;50:113-116[PMID:16252575]
11 Baranova A,Younossi ZM.The future is around the corner:Noninvasive diagnosis of progressive nonalcoholic steatohepatitis.Hepatology 2008;47:373-375[PMID:18220279 DOI:10.1002/hep.22140]
12 Poynard T,Ratziu V,Naveau S,Thabut D,Charlotte F,Messous D,Capron D,Abella A,Massard J,Ngo Y,Munteanu M,Mercadier A,Manns M,Albrecht J.The diagnostic value of biomarkers(Steato Test)for the prediction of liver steatosis.Comp Hepatol2005;4:10[PMID:16375767 DOI:10.1186/1476-5926-4-10]
13 Castera L.Non-invasive diagnosis of steatosis and fibrosis.Diabetes Metab 2008;34:674-679[PMID:19195629 DOI:10.1016/S1262-3636(08)74603-2]
14 Bondini S,Kleiner DE,Goodman ZD,Gramlich T,Younossi ZM.Pathologic assessment of non-alcoholic fatty liver disease.Clin Liver Dis 2007;11:17-23,vii[PMID:17544969 DOI:10.1016/j.cld.2007.02.002]
15 Ratziu V,Charlotte F,Heurtier A,Gombert S,Giral P,Bruckert E,Grimaldi A,Capron F,Poynard T.Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology 2005;128:1898-1906[PMID:15940625]
16 Manousou P,Kalambokis G,Grillo F,Watkins J,Xirouchakis E,Pleguezuelo M,Leandro G,Arvaniti V,Germani G,Patch D,Calvaruso V,Mikhailidis DP,Dhillon AP,Burroughs AK.Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.Liver Int 2011;31:730-739[PMID:21457446 DOI:10.1111/j.1478-3231.2011.02488.x]
17 Wilson S,Chalasani N.Noninvasive markers of advanced histology in nonalcoholic fatty liver disease:are we there yet?Gastroenterology 2007;133:1377-1378;discussion 1378-1379[PMID:17919509 DOI:10.1053/j.gastro.2007.08.045]
18 Díez-Vallejo J,Comas-Fuentes A.Asymptomatic hypertransaminasemia in patients in primary care.Rev Esp Enferm Dig 2011;103:530-535[PMID:22054268]
19 Hossain N,Afendy A,Stepanova M,Nader F,Srishord M,Rafiq N,Goodman Z,Younossi Z.Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol 2009;7:1224-1229,1229e1-e2[PMID:19559819 DOI:10.1016/j.cgh.2009.06.007]
20 Wilfred de Alwis NM,Day CP.Genetics of alcoholic liver disease and nonalcoholic fatty liver disease.Semin Liver Dis 2007;27:44-54[PMID:17295176 DOI:10.1055/s-2006-960170]
21 Ioannou GN,Boyko EJ,Lee SP.The prevalence and predictors of elevated serum aminotransferase activity in the United States in1999-2002.Am J Gastroenterol 2006;101:76-82[PMID:16405537DOI:10.1111/j.1572-0241.2005.00341.x]
22 Esteghamati A,Jamali A,Khalilzadeh O,Noshad S,Khalili M,Zandieh A,Morteza A,Nakhjavani M.Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.Diabetol Metab Syndr 2010;2:65[PMID:21047423DOI:10.1186/1758-5996-2-65]
23 Koga M,Saito H,Mukai M,Saibara T,Kasayama S.Serum dehydroepiandrosterone sulphate levels in patients with nonalcoholic fatty liver disease.Intern Med 2011;50:1657-1661[PMID:21841322]
24 Pourshams A,Malekzadeh R,Monavvari A,Akbari MR,Mohamadkhani A,Yarahmadi S,Seddighi N,Mohamadnejad M,Sotoudeh M,Madjlessi A.Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors.J Gastroenterol Hepatol 2005;20:229-233[PMID:15683425 DOI:10.1111/j.1440-1746.2004.03511.x]
25 Fracanzani AL,Valenti L,Bugianesi E,Andreoletti M,Colli A,Vanni E,Bertelli C,Fatta E,Bignamini D,Marchesini G,Fargion S.Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels:a role for insulin resistance and diabetes.Hepatology 2008;48:792-798[PMID:18752331 DOI:10.1002/hep.22429]
26 Neuschwander-Tetri BA,Clark JM,Bass NM,Van Natta ML,Unalp-Arida A,Tonascia J,Zein CO,Brunt EM,Kleiner DE,Mc Cullough AJ,Sanyal AJ,Diehl AM,Lavine JE,Chalasani N,Kowdley KV.Clinical,laboratory and histological associations in adults with nonalcoholic fatty liver disease.Hepatology 2010;52:913-924[PMID:20648476 DOI:10.1002/hep.23784]
27 Ratziu V,Giral P,Charlotte F,Bruckert E,Thibault V,Theodorou I,Khalil L,Turpin G,Opolon P,Poynard T.Liver fibrosis in overweight patients.Gastroenterology 2000;118:1117-1123[PMID:10833486]
28 Sumida Y,Yoneda M,Hyogo H,Itoh Y,Ono M,Fujii H,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Fujita K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T.Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.BMC Gastroenterol 2012;12:2[PMID:22221544 DOI:10.1186/1471-230X-12-2]
29 Ratziu V,Giral P,Munteanu M,Messous D,Mercadier A,Bernard M,Morra R,Imbert-Bismut F,Bruckert E,Poynard T.Screening for liver disease using non-invasive biomarkers(Fibro Test,Steato Test and Nash Test)in patients with hyperlipidaemia.Aliment Pharmacol Ther 2007;25:207-218[PMID:17229244 DOI:10.1111/j.1365-2036.2006.03182.x]
30 Calès P,Boursier J,Chaigneau J,LainéF,Sandrini J,Michalak S,Hubert I,Dib N,Oberti F,Bertrais S,Hunault G,Cavaro-Ménard C,Gallois Y,Deugnier Y,Rousselet MC.Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.Liver Int 2010;30:1346-1354[PMID:20666992 DOI:10.1111/j.1478-3231.2010.02314.x]
31 Browning JD.Statins and hepatic steatosis:perspectives from the Dallas Heart Study.Hepatology 2006;44:466-471[PMID:16871575 DOI:10.1002/hep.21248]
32 Bedogni G,Miglioli L,Masutti F,Tiribelli C,Marchesini G,Bellentani S.Prevalence of and risk factors for nonalcoholic fatty liver disease:the Dionysos nutrition and liver study.Hepatology2005;42:44-52[PMID:15895401 DOI:10.1002/hep.20734]
33 Browning JD,Szczepaniak LS,Dobbins R,Nuremberg P,Horton JD,Cohen JC,Grundy SM,Hobbs HH.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity.Hepatology 2004;40:1387-1395[PMID:15565570 DOI:10.1002/hep.20466]
34 Gholam PM,Flancbaum L,Machan JT,Charney DA,Kotler DP.Nonalcoholic fatty liver disease in severely obese subjects.Am JGastroenterol 2007;102:399-408[PMID:17311652 DOI:10.1111/j.1572-0241.2006.01041.x]
35 Chang Y,Ryu S,Sung E,Jang Y.Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease.Clin Chem 2007;53:686-692[PMID:17272484DOI:10.1373/clinchem.2006.081257]
36 Leite NC,Salles GF,Araujo AL,Villela-Nogueira CA,Cardoso CR.Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.Liver Int 2009;29:113-119[PMID:18384521 DOI:10.1111/j.1478-3231.2008.01718.x]
37 M’Kada H,Munteanu M,Perazzo H,Ngo Y,Ramanujam N,Imbert-Bismut F,Ratziu V,Bonnefont-Rousselot D,Souberbielle B,Schuppe-Koistinen I,Poynard T.What are the best reference values for a normal serum alanine transaminase activity(ALT)?Impact on the presumed prevalence of drug induced liver injury(DILI).Regul Toxicol Pharmacol 2011;60:290-295[PMID:21539883 DOI:10.1016/j.yrtph.2011.04.002]
38 Prati D,Taioli E,Zanella A,Della Torre E,Butelli S,Del Vecchio E,Vianello L,Zanuso F,Mozzi F,Milani S,Conte D,Colombo M,Sirchia G.Updated definitions of healthy ranges for serum alanine aminotransferase levels.Ann Intern Med 2002;137:1-10[PMID:12093239]
39 Miyake T,Kumagi T,Hirooka M,Koizumi M,Furukawa S,Ueda T,Tokumoto Y,Ikeda Y,Abe M,Kitai K,Hiasa Y,Matsuura B,Onji M.Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease:a community-based cross-sectional study.J Gastroenterol 2012;47:696-703[PMID:22331365 DOI:10.1007/s00535-012-0534-y]
40 Kaplan MM.Alanine aminotransferase levels:what’s normal?Ann Intern Med 2002;137:49-51[PMID:12093245 DOI:10.7326/0003-4819-137-1-200207020-00012]
41 Uslusoy HS,Nak SG,Gülten M,Biyikli Z.Non-alcoholic steatohepatitis with normal aminotransferase values.World JGastroenterol 2009;15:1863-1868[PMID:19370784 DOI:10.3748/wjg.15.1863]
42 Kayadibi H,Gültepe M,Yasar B,Ince AT,Ozcan O,Ipcioglu OM,Kurdas OO,Bolat B,Benek YZ,Guveli H,Atalay S,Ozkara S,Keskin O.Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease:a surrogate marker to distinguish steatohepatitis from simple steatosis.Dig Dis Sci 2009;54:1764-1771[PMID:18989777 DOI:10.1007/s10620-008-0535-0]
43 Riquelme A,Arrese M,Soza A,Morales A,Baudrand R,PérezAyuso RM,González R,Alvarez M,Hernández V,García-Zattera MJ,Otarola F,Medina B,Rigotti A,Miquel JF,Marshall G,Nervi F.Non-alcoholic fatty liver disease and its association with obesity,insulin resistance and increased serum levels of C-reactive protein in Hispanics.Liver Int 2009;29:82-88[PMID:18647235 DOI:10.1111/j.1478-3231.2008.01823.x]
44 Shi JP,Xun YH,Hu CB,Zhang L,Liu H,Lou GQ,Fan JG.Clinical and histological features of non-alcoholic fatty liver disease.Zhonghua Ganzangbing Zazhi 2009;17:812-816[PMID:19958638]
45 Prashanth M,Ganesh HK,Vima MV,John M,Bandgar T,Joshi SR,Shah SR,Rathi PM,Joshi AS,Thakkar H,Menon PS,Shah NS.Prevalence of nonalcoholic fatty liver disease in patients with type2 diabetes mellitus.J Assoc Physicians India 2009;57:205-210[PMID:19588648]
46 Kashyap SR,Diab DL,Baker AR,Yerian L,Bajaj H,GrayMc Guire C,Schauer PR,Gupta M,Feldstein AE,Hazen SL,Stein CM.Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.Obesity(Silver Spring)2009;17:1696-1701[PMID:19360015 DOI:10.1038/oby.2009.89]
47 Charatcharoenwitthaya P,Lindor KD,Angulo P.The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease.Dig Dis Sci 2012;57:1925-1931[PMID:22373863DOI:10.1007/s10620-012-2098-3]
48 Kaneda H,Hashimoto E,Yatsuji S,Tokushige K,Shiratori K.Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2006;21:1459-1465[PMID:16911693 DOI:10.1111/j.1440-1746.2006.04447.x]
49 Hsieh MH,Ho CK,Hou NJ,Hsieh MY,Lin WY,Yang JF,Chiu CC,Huang JF,Chang NC,Wang CL,Dai CY,Chuang WL,Yu ML.Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C.Int J Obes(Lond)2009;33:1309-1317[PMID:19752878DOI:10.1038/ijo.2009.172]
50 Fan JG,Saibara T,Chitturi S,Kim BI,Sung JJ,Chutaputti A.What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?J Gastroenterol Hepatol 2007;22:794-800[PMID:17498218 DOI:10.1111/j.1440-1746.2007.04952.x]
51 Munteanu M,Ratziu V,Morra R,Messous D,Imbert-Bismut F,Poynard T.Noninvasive biomarkers for the screening of fibrosis,steatosis and steatohepatitis in patients with metabolic risk factors:Fibro Test-Fibro Max experience.J Gastrointestin Liver Dis 2008;17:187-191[PMID:18568141]
52 Poynard T,Ratziu V,Charlotte F,Messous D,Munteanu M,ImbertBismut F,Massard J,Bonyhay L,Tahiri M,Thabut D,Cadranel JF,Le Bail B,de Ledinghen V.Diagnostic value of biochemical markers(Nash Test)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol2006;6:34[PMID:17096854 DOI:10.1186/1471-230X-6-34]
53 Angulo P,Hui JM,Marchesini G,Bugianesi E,George J,Farrell GC,Enders F,Saksena S,Burt AD,Bida JP,Lindor K,Sanderson SO,Lenzi M,Adams LA,Kench J,Therneau TM,Day CP.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45:846-854[PMID:17393509 DOI:10.1002/hep.21496]
54 Wong VW,Wong GL,Chim AM,Tse AM,Tsang SW,Hui AY,Choi PC,Chan AW,So WY,Chan FK,Sung JJ,Chan HL.Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.Am J Gastroenterol 2008;103:1682-1688[PMID:18616651 DOI:10.1111/j.1572-0241.2008.01933.x]
55 Calès P,LainéF,Boursier J,Deugnier Y,Moal V,Oberti F,Hunault G,Rousselet MC,Hubert I,Laafi J,Ducluzeaux PH,Lunel F.Comparison of blood tests for liver fibrosis specific or not to NAFLD.J Hepatol 2009;50:165-173[PMID:18977552 DOI:10.1016/j.jhep.2008.07.035]
56 Younossi ZM,Page S,Rafiq N,Birerdinc A,Stepanova M,Hossain N,Afendy A,Younoszai Z,Goodman Z,Baranova A.A biomarker panel for non-alcoholic steatohepatitis(NASH)and NASH-related fibrosis.Obes Surg 2011;21:431-439[PMID:20532833 DOI:10.1007/s11695-010-0204-1]
57 Palekar NA,Naus R,Larson SP,Ward J,Harrison SA.Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.Liver Int 2006;26:151-156[PMID:16448452 DOI:10.1111/j.1478-3231.2005.01209.x]
58 Harrison SA,Oliver D,Arnold HL,Gogia S,NeuschwanderTetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut 2008;57:1441-1447[PMID:18390575 DOI:10.1136/gut.2007.146019]
59 Kruger FC,Daniels CR,Kidd M,Swart G,Brundyn K,van Rensburg C,Kotze M.APRI:a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.S Afr Med J 2011;101:477-480[PMID:21920102]
60 Yoshida M.Novel role of NPC1L1 in the regulation of hepatic metabolism:potential contribution of ezetimibe in NAFLD/NASHtreatment.Curr Vasc Pharmacol 2011;9:121-123[PMID:21044016]
61 Rafiq N,Bai C,Fang Y,Srishord M,Mc Cullough A,Gramlich T,Younossi ZM.Long-term follow-up of patients with nonalcoholic fatty liver.Clin Gastroenterol Hepatol 2009;7:234-238[PMID:19049831 DOI:10.1016/j.cgh.2008.11.005]
62 Fierbinteanu-Braticevici C,Baicus C,Tribus L,Papacocea R.Predictive factors for nonalcoholic steatohepatitis(NASH)in patients with nonalcoholic fatty liver disease(NAFLD).JGastrointestin Liver Dis 2011;20:153-159[PMID:21725512]
63 Younossi ZM,Gramlich T,Matteoni CA,Boparai N,Mc Cullough AJ.Nonalcoholic fatty liver disease in patients with type 2 diabetes.Clin Gastroenterol Hepatol 2004;2:262-265[PMID:15017611]
64 Suzuki A,Angulo P,Lymp J,Li D,Satomura S,Lindor K.Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.Liver Int 2005;25:779-786[PMID:15998429 DOI:10.1111/j.1478-3231.2005.01064.x]
65 Sumida Y,Yonei Y,Kanemasa K,Hara T,Inada Y,Sakai K,Imai S,Hibino S,Yamaguchi K,Mitsuyoshi H,Yasui K,Minami M,Itoh Y,Naito Y,Yoshikawa T,Okanoue T.Lower circulating levels of dehydroepiandrosterone,independent of insulin resistance,is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients.Hepatol Res 2010;40:901-910[PMID:20887595 DOI:10.1111/j.1872-034X.2010.00704.x]
66 Mawatari H,Yoneda M,Kirikoshi H,Maeda S,Nakajima A,Saito S.Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease.J Gastroenterol 2012;47:606-607;author reply 608[PMID:22388885]
67 Yoneda M,Fujii H,Sumida Y,Hyogo H,Itoh Y,Ono M,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Imajo K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T.Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.J Gastroenterol 2011;46:1300-1306[PMID:21750883DOI:10.1007/s00535-011-0436-4]
68 Celikbilek M,Gürsoy S,Deniz K,Karaman A,Zararsiz G,Yurci A.Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease.Platelets 2013;24:194-199[PMID:22646469 DOI:10.3109/09537104.2012.688898]
69 Ozhan H,Aydin M,Yazici M,Yazgan O,Basar C,Gungor A,Onder E.Mean platelet volume in patients with non-alcoholic fatty liver disease.Platelets 2010;21:29-32[PMID:19947902 DOI:10.3109/09537100903391023]
70 Shin WY,Jung DH,Shim JY,Lee HR.The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population.Platelets 2011;22:442-446[PMID:21751850 DOI:10.3109/09537104.2010.540049]
71 Kilciler G,Genc H,Tapan S,Ors F,Kara M,Karadurmus N,Ercin CN,Karslioglu Y,Kilic S,Bagci S,Erbil MK,Dogru T.Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease.Ups J Med Sci 2010;115:253-259[PMID:20731535 DOI:10.3109/03009734.2010.500062]
72 Hashimoto E,Farrell GC.Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?J Gastroenterol Hepatol 2009;24:501-503[PMID:19368628 DOI:10.1111/j.1440-1746.2009.05806.x]
73 Siebler J,Galle PR,Weber MM.The gut-liver-axis:endotoxemia,inflammation,insulin resistance and NASH.J Hepatol 2008;48:1032-1034[PMID:18468548 DOI:10.1016/j.jhep.2008.03.007]
74 Kogiso T,Moriyoshi Y,Shimizu S,Nagahara H,Shiratori K.Highsensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population.J Gastroenterol 2009;44:313-321[PMID:19271113 DOI:10.1007/s00535-009-0002-5]
75 Kerner A,Avizohar O,Sella R,Bartha P,Zinder O,Markiewicz W,Levy Y,Brook GJ,Aronson D.Association between elevated liver enzymes and C-reactive protein:possible hepatic contribution to systemic inflammation in the metabolic syndrome.Arterioscler Thromb Vasc Biol 2005;25:193-197[PMID:15499043 DOI:10.1161/01.ATV.0000148324.63685.6a]
76 Yoneda M,Mawatari H,Fujita K,Iida H,Yonemitsu K,Kato S,Takahashi H,Kirikoshi H,Inamori M,Nozaki Y,Abe Y,Kubota K,Saito S,Iwasaki T,Terauchi Y,Togo S,Maeyama S,Nakajima A.High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis(NASH)and also of the severity of fibrosis in NASH.J Gastroenterol 2007;42:573-582[PMID:17653654 DOI:10.1007/s00535-007-2060-x]
77 Uchihara M,Izumi N.[High-sensitivity C-reactive protein(hsCRP):a promising biomarker for the screening of non-alcoholic steatohepatitis(NASH)].Nihon Rinsho 2006;64:1133-1138[PMID:16768121]
78 Zimmermann E,Anty R,Tordjman J,Verrijken A,Gual P,Tran A,Iannelli A,Gugenheim J,Bedossa P,Francque S,Le MarchandBrustel Y,Clement K,Van Gaal L,S?rensen TI,Jess T.C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.J Hepatol 2011;55:660-665[PMID:21238518 DOI:10.1016/j.jhep.2010.12.017]
79 Park SH,Kim BI,Yun JW,Kim JW,Park DI,Cho YK,Sung IK,Park CY,Sohn CI,Jeon WK,Kim H,Rhee EJ,Lee WY,Kim SW.Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.JGastroenterol Hepatol 2004;19:694-698[PMID:15151626 DOI:10.1111/j.1440-1746.2004.03362.x]
80 Anty R,Bekri S,Luciani N,Saint-Paul MC,Dahman M,Iannelli A,Amor IB,Staccini-Myx A,Huet PM,Gugenheim J,Sadoul JL,Le Marchand-Brustel Y,Tran A,Gual P.The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome,Type 2diabetes,and NASH.Am J Gastroenterol 2006;101:1824-1833[PMID:16790033 DOI:10.1111/j.1572-0241.2006.00724.x]
81 Park HS,Park JY,Yu R.Relationship of obesity and visceral adiposity with serum concentrations of CRP,TNF-alpha and IL-6.Diabetes Res Clin Pract 2005;69:29-35[PMID:15955385 DOI:10.1016/j.diabres.2004.11.007]
82 Sivapackianathan R,Asivatham AJ,Al-Mahtab M,Chowdhury TA.Association between non-alcoholic fatty liver disease and metabolic syndrome.Int J Hepatol 2010;1:17-24
83 Khera A,Vega GL,Das SR,Ayers C,Mc Guire DK,Grundy SM,de Lemos JA.Sex differences in the relationship between C-reactive protein and body fat.J Clin Endocrinol Metab 2009;94:3251-3258[PMID:19567538 DOI:10.1210/jc.2008-2406]
84 Lakoski SG,Cushman M,Criqui M,Rundek T,Blumenthal RS,D’Agostino RB,Herrington DM.Gender and C-reactive protein:data from the Multiethnic Study of Atherosclerosis(MESA)cohort.Am Heart J 2006;152:593-598[PMID:16923436 DOI:10.1016/j.ahj.2006.02.015]
85 Khera A,Mc Guire DK,Murphy SA,Stanek HG,Das SR,Vongpatanasin W,Wians FH,Grundy SM,de Lemos JA.Race and gender differences in C-reactive protein levels.J Am Coll Cardiol 2005;46:464-469[PMID:16053959 DOI:10.1016/j.jacc.2005.04.051]
86 Das I.Raised C-reactive protein levels in serum from smokers.Clin Chim Acta 1985;153:9-13[PMID:2416495]
87 Tsochatzis EA,Papatheodoridis GV,Archimandritis AJ.Adipokines in nonalcoholic steatohepatitis:from pathogenesis to implications in diagnosis and therapy.Mediators Inflamm 2009;2009:831670[PMID:19753129 DOI:10.1155/2009/831670]
88 Oda E,Watanabe K.High-sensitivity C-reactive protein and metabolic syndrome(insulin resistance syndrome),including nonalcoholic steatohepatitis.J Gastroenterol 2008;43:312-313;author reply 313[PMID:18458848 DOI:10.1007/s00535-008-2175-8]
89 Kowdley KV,Belt P,Wilson LA,Yeh MM,NeuschwanderTetri BA,Chalasani N,Sanyal AJ,Nelson JE.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.Hepatology 2012;55:77-85[PMID:21953442 DOI:10.1002/hep.24706]
90 Oh MK,Winn J,Poordad F.Review article:diagnosis and treatment of non-alcoholic fatty liver disease.Aliment Pharmacol Ther 2008;28:503-522[PMID:18532991 DOI:10.1111/j.1365-2036.2008.03752.x]
91 Sumida Y,Yoneda M,Hyogo H,Yamaguchi K,Ono M,Fujii H,Eguchi Y,Suzuki Y,Imai S,Kanemasa K,Fujita K,Chayama K,Yasui K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Okanoue T.A simple clinical scoring system using ferritin,fasting insulin,and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.J Gastroenterol 2011;46:257-268[PMID:20842510 DOI:10.1007/s00535-010-0305-6]
92 Polyzos SA,Kountouras J,Patsiaoura K,Katsiki E,Zafeiriadou E,Deretzi G,Zavos C,Gavalas E,Katsinelos P,Mane V,Slavakis A.Serum homocysteine levels in patients with nonalcoholic fatty liver disease.Ann Hepatol 2012;11:68-76[PMID:22166563]
93 Blendis L,Oren R,Halpern Z.NASH:Can we iron out the pathogenesis?Gastroenterology 2000;118:981-983[PMID:10784602 DOI:10.1016/S0016-5085(00)70189-2]
94 Yoneda M,Mawatari H,Fujita K,Yonemitsu K,Kato S,Takahashi H,Kirikoshi H,Inamori M,Nozaki Y,Abe Y,Kubota K,Saito S,Iwasaki T,Terauchi Y,Togo S,Maeyama S,Nakajima A.Type IVcollagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.J Gastroenterol 2007;42:375-381[PMID:17530362 DOI:10.1007/s00535-007-2014-3]
95 Yoneda M,Uchiyama T,Kato S,Endo H,Fujita K,Yoneda K,Mawatari H,Iida H,Takahashi H,Kirikoshi H,Inamori M,Nozaki Y,Kobayashi N,Kubota K,Saito S,Maeyama S,Sagara M,Aburatani H,Kodama T,Nakajima A.Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis(NASH).BMC Gastroenterol 2008;8:53[PMID:19014569 DOI:10.1186/1471-230X-8-53]
96 Polyzos SA,Kountouras J,Zavos C.Nonalcoholic fatty liver disease:the pathogenetic roles of insulin resistance and adipocytokines.Curr Mol Med 2009;9:299-314[PMID:19355912]
97 Yalniz M,Bahcecioglu IH,Ataseven H,Ustundag B,Ilhan F,Poyrazoglu OK,Erensoy A.Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis.Mediators Inflamm 2006;2006:34295[PMID:17392582 DOI:10.1155/MI/2006/34295]
98 Jarrar MH,Baranova A,Collantes R,Ranard B,Stepanova M,Bennett C,Fang Y,Elariny H,Goodman Z,Chandhoke V,Younossi ZM.Adipokines and cytokines in non-alcoholic fatty liver disease.Aliment Pharmacol Ther 2008;27:412-421[PMID:18081738DOI:10.1111/j.1365-2036.2007.03586.x]
99 Tilg H.The role of cytokines in non-alcoholic fatty liver disease.Dig Dis 2010;28:179-185[PMID:20460908 DOI:10.1159/000282083]
100 Hui JM,Hodge A,Farrell GC,Kench JG,Kriketos A,George J.Beyond insulin resistance in NASH:TNF-alpha or adiponectin?Hepatology 2004;40:46-54[PMID:15239085 DOI:10.1002/hep.20280]
101 Buechler C,Wanninger J,Neumeier M.Adiponectin,a key adipokine in obesity related liver diseases.World J Gastroenterol2011;17:2801-2811[PMID:21734787 DOI:10.3748/wjg.v17.i23.2801]
102 Aller R,de Luis DA,Fernandez L,Calle F,Velayos B,Olcoz JL,Izaola O,Sagrado MG,Conde R,Gonzalez JM.Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease.Dig Dis Sci 2008;53:1088-1092[PMID:17934820 DOI:10.1007/s10620-007-9981-3]
103 Musso G,Gambino R,Durazzo M,Biroli G,Carello M,FagàE,Pacini G,De Michieli F,Rabbione L,Premoli A,Cassader M,Pagano G.Adipokines in NASH:postprandial lipid metabolism as a link between adiponectin and liver disease.Hepatology 2005;42:1175-1183[PMID:16231364 DOI:10.1002/hep.20896]
104 Shimada M,Kawahara H,Ozaki K,Fukura M,Yano H,Tsuchishima M,Tsutsumi M,Takase S.Usefulness of a combined evaluation of the serum adiponectin level,HOMA-IR,and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.Am J Gastroenterol 2007;102:1931-1938[PMID:17511754 DOI:10.1111/j.1572-0241.2007.01322.x]
105 Tokushige K,Hashimoto E,Noto H,Yatsuji S,Taniai M,Torii N,Shiratori K.Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease.JGastroenterol 2009;44:976-982[PMID:19484180 DOI:10.1007/s00535-009-0085-z]
106 Kaser S,Moschen A,Cayon A,Kaser A,Crespo J,Pons-Romero F,Ebenbichler CF,Patsch JR,Tilg H.Adiponectin and its receptors in non-alcoholic steatohepatitis.Gut 2005;54:117-121[PMID:15591515 DOI:10.1136/gut.2003.037010]
107 Younossi ZM,Jarrar M,Nugent C,Randhawa M,Afendy M,Stepanova M,Rafiq N,Goodman Z,Chandhoke V,Baranova A.Anovel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis(NASH).Obes Surg 2008;18:1430-1437[PMID:18500507 DOI:10.1007/s11695-008-9506-y]
108 Bethanis SK,Theocharis SE.Leptin in the field of hepatic fibrosis:a pivotal or an incidental player?Dig Dis Sci 2006;51:1685-1696[PMID:16958000 DOI:10.1007/s10620-006-9126-0]
109 Uygun A,Kadayifci A,Yesilova Z,Erdil A,Yaman H,Saka M,Deveci MS,Bagci S,Gulsen M,Karaeren N,Dagalp K.Serum leptin levels in patients with nonalcoholic steatohepatitis.Am J Gastroenterol 2000;95:3584-3589[PMID:11151896 DOI:10.1111/j.1572-0241.2000.03297.x]
110 Polyzos SA,Kountouras J,Zavos C,Deretzi G.The potential adverse role of leptin resistance in nonalcoholic fatty liver disease:a hypothesis based on critical review of the literature.J Clin Gastroenterol 2011;45:50-54[PMID:20717042 DOI:10.1097/MCG.0b013e3181ec5c66]
111 Chan JL,Wong SL,Mantzoros CS.Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states:regulation by gender and adiposity.Clin Pharmacokinet 2008;47:753-764[PMID:18840030 DOI:10.2165/00003088-200847110-00006]
112 Lo KM,Zhang J,Sun Y,Morelli B,Lan Y,Lauder S,Brunkhorst B,Webster G,Hallakou-Bozec S,DoaréL,Gillies SD.Engineering a pharmacologically superior form of leptin for the treatment of obesity.Protein Eng Des Sel 2005;18:1-10[PMID:15790575DOI:10.1093/protein/gzh102]
113 Zelissen PM,Stenlof K,Lean ME,Fogteloo J,Keulen ET,Wilding J,Finer N,R?ssner S,Lawrence E,Fletcher C,Mc Camish M.Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults:a randomized,placebo-controlled trial.Diabetes Obes Metab 2005;7:755-761[PMID:16219020DOI:10.1111/j.1463-1326.2005.00468.x]
114 Chitturi S,Farrell G,Frost L,Kriketos A,Lin R,Fung C,Liddle C,Samarasinghe D,George J.Serum leptin in NASH correlates with hepatic steatosis but not fibrosis:a manifestation of lipotoxicity?Hepatology 2002;36:403-409[PMID:12143049 DOI:10.1053/jhep.2002.34738]
115 Mantzoros CS,Moschos S,Avramopoulos I,Kaklamani V,Liolios A,Doulgerakis DE,Griveas I,Katsilambros N,Flier JS.Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans.J Clin Endocrinol Metab 1997;82:3408-3413[PMID:9329377 DOI:10.1210/jcem.82.10.4323]
116 Nakao K,Nakata K,Ohtsubo N,Maeda M,Moriuchi T,Ichikawa T,Hamasaki K,Kato Y,Eguchi K,Yukawa K,Ishii N.Association between nonalcoholic fatty liver,markers of obesity,and serum leptin level in young adults.Am J Gastroenterol 2002;97:1796-1801[PMID:12135038 DOI:10.1111/j.1572-0241.2002.05846.x]
117 Canbakan B,Tahan V,Balci H,Hatemi I,Erer B,Ozbay G,Sut N,Hacibekiroglu M,Imeryuz N,Senturk H.Leptin in nonalcoholic fatty liver disease.Ann Hepatol 2008;7:249-254[PMID:18753993]
118 Serin E,Ozer B,GümürdülüY,Kayasel?uk F,Kul K,Boyacio?lu S.Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver.J Gastroenterol 2003;38:471-476[PMID:12768390 DOI:10.1007/s00535-002-1084-5]
119 Procaccini C,Galgani M,De Rosa V,Carbone F,La Rocca C,Ranucci G,Iorio R,Matarese G.Leptin:the prototypic adipocytokine and its role in NAFLD.Curr Pharm Des 2010;16:1902-1912[PMID:20370676]
120 Torres DM,Harrison SA.Diagnosis and therapy of nonalcoholic steatohepatitis.Gastroenterology 2008;134:1682-1698[PMID:18471547 DOI:10.1053/j.gastro.2008.02.077]
121 Lydatakis H,Hager IP,Kostadelou E,Mpousmpoulas S,Pappas S,Diamantis I.Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.Liver Int 2006;26:864-871[PMID:16911470 DOI:10.1111/j.1478-3231.2006.01312.x]
122 Fon Tacer K,Kuzman D,Seliskar M,Pompon D,Rozman D.TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes.Physiol Genomics 2007;31:216-227[PMID:17566076 DOI:10.1152/physiolgenomics.00264.2006]
123 Feingold KR,Soued M,Serio MK,Adi S,Moser AH,Grunfeld C.The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis.Metabolism 1990;39:623-632[PMID:2352479]
124 Das SK,Balakrishnan V.Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease.Indian J Clin Biochem 2011;26:202-209[PMID:22468051 DOI:10.1007/s12291-011-0121-7]
125 Aigner E,Theurl I,Theurl M,Lederer D,Haufe H,Dietze O,Strasser M,Datz C,Weiss G.Pathways underlying iron accumulation in human nonalcoholic fatty liver disease.Am J Clin Nutr 2008;87:1374-1383[PMID:18469261]
126 Bahcecioglu IH,Yalniz M,Ataseven H,Ilhan N,Ozercan IH,Seckin D,Sahin K.Levels of serum hyaluronic acid,TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.Hepatogastroenterology 2005;52:1549-1553[PMID:16201116]
127 Lebensztejn DM,Kowalczuk D,Tarasów E,Skiba E,Kaczmarski M.Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD.Adv Med Sci 2010;55:74-79[PMID:20371430 DOI:10.2478/v10039-010-0008-5]
128 Kugelmas M,Hill DB,Vivian B,Marsano L,Mc Clain CJ.Cytokines and NASH:a pilot study of the effects of lifestyle modification and vitamin E.Hepatology 2003;38:413-419[PMID:12883485 DOI:10.1053/jhep.2003.50]
129 Ferreira VS,Pernambuco RB,Lopes EP,Morais CN,Rodrigues MC,Arruda MJ,Silva LM,Vilar L.Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.Arq Bras Endocrinol Metabol 2010;54:362-368[PMID:20625647 DOI:10.1590/S0004-27302010000400004]
130 Hui JM,Farrell GC,Kench JG,George J.High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD.Hepatology 2004;39:1458-1459[PMID:15122781 DOI:10.1002/hep.20223]
131 Zamora-Valdés D,Méndez-Sánchez N.Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis.Ann Hepatol 2007;6:281-283[PMID:18007563]
132 Abiru S,Migita K,Maeda Y,Daikoku M,Ito M,Ohata K,Nagaoka S,Matsumoto T,Takii Y,Kusumoto K,Nakamura M,Komori A,Yano K,Yatsuhashi H,Eguchi K,Ishibashi H.Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis.Liver Int 2006;26:39-45[PMID:16420507 DOI:10.1111/j.1478-3231.2005.01191.x]
133 Yilmaz Y,Kedrah AE,Ozdogan O.Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.World J Gastroenterol 2009;15:4387-4391[PMID:19764089 DOI:10.3748/wjg.15.4387]
134 Wieckowska A,Zein NN,Yerian LM,Lopez AR,Mc Cullough AJ,Feldstein AE.In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.Hepatology 2006;44:27-33[PMID:16799979 DOI:10.1002/hep.21223]
135 Ulukaya E,Yilmaztepe A,Akgoz S,Linder S,Karadag M.The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.Lung Cancer 2007;56:399-404[PMID:17316892 DOI:10.1016/j.lungcan.2007.01.015]
136 Tarantino G,Conca P,Coppola A,Vecchione R,Di Minno G.Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis.Eur JClin Invest 2007;37:48-53[PMID:17181567 DOI:10.1111/j.1365-2362.2007.01745.x]
137 Wieckowska A,Lopez AR,Zein NN,Mc Cullough AJ,Feldstein AE.Noninvasive assessment of hepatocyte apoptosis in nonalcoholic fatty liver disease;a multi-center validation study.Gastroenterology 2007;132:A729[DOI:10.1002/hep.23050]
138 Diab DL,Yerian L,Schauer P,Kashyap SR,Lopez R,Hazen SL,Feldstein AE.Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.Clin Gastroenterol Hepatol 2008;6:1249-1254[PMID:18995215 DOI:10.1016/j.cgh.2008.07.016]
139 Musso G,Gambino R,Cassader M,Pagano G.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity.Ann Med 2011;43:617-649[PMID:21039302 DOI:10.3109/07853890.2010.518623]
140 Malik R,Chang M,Bhaskar K,Nasser I,Curry M,Schuppan D,Byrnes V,Afdhal N.The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2009;24:564-568[PMID:19378390]
141 Rosenberg WM,Voelker M,Thiel R,Becka M,Burt A,Schuppan D,Hubscher S,Roskams T,Pinzani M,Arthur MJ.Serum markers detect the presence of liver fibrosis:a cohort study.Gastroenterology 2004;127:1704-1713[PMID:15578508]
142 Feldstein AE,Wieckowska A,Lopez AR,Liu YC,Zein NN,Mc Cullough AJ.Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis:a multicenter validation study.Hepatology 2009;50:1072-1078[PMID:19585618]
143 Sakugawa H,Nakayoshi T,Kobashigawa K,Yamashiro T,Maeshiro T,Miyagi S,Shiroma J,Toyama A,Nakayoshi T,Kinjo F,Saito A.Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.World JGastroenterol 2005;11:255-259[PMID:15633226]
144 Santos VN,Leite-Mór MM,Kondo M,Martins JR,Nader H,Lanzoni VP,Parise ER.Serum laminin,type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease.Braz J Med Biol Res 2005;38:747-753[PMID:15917956]
145 Miele L,Forgione A,La Torre G,Vero V,Cefalo C,Racco S,Vellone VG,Vecchio FM,Gasbarrini G,Rapaccini GL,Neuman MG,Grieco A.Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.Transl Res 2009;154:194-201[PMID:19766963 DOI:10.1016/j.trsl.2009.06.007]
146 Preiss D,Sattar N.Non-alcoholic fatty liver disease:an overview of prevalence,diagnosis,pathogenesis and treatment considerations.Clin Sci(Lond)2008;115:141-150[PMID:18662168 DOI:10.1042/CS20070402]
147 Dowman JK,Tomlinson JW,Newsome PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis.Aliment Pharmacol Ther 2011;33:525-540[PMID:21198708 DOI:10.1111/j.1365-2036.2010.04556.x]
148 Lesmana CR,Hasan I,Budihusodo U,Gani RA,Krisnuhoni E,Akbar N,Lesmana LA.Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis.J Dig Dis 2009;10:201-206[PMID:19659788DOI:10.1111/j.1751-2980.2009.00386.x]
149 Charlton M,Angulo P,Chalasani N,Merriman R,Viker K,Charatcharoenwitthaya P,Sanderson S,Gawrieh S,Krishnan A,Lindor K.Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.Hepatology2008;47:484-492[PMID:18220286 DOI:10.1002/hep.22063]
150 Baulieu EE,Thomas G,Legrain S,Lahlou N,Roger M,Debuire B,Faucounau V,Girard L,Hervy MP,Latour F,Leaud MC,Mokrane A,Pitti-Ferrandi H,Trivalle C,de Lacharrière O,Nouveau S,RakotoArison B,Souberbielle JC,Raison J,Le Bouc Y,Raynaud A,Girerd X,Forette F.Dehydroepiandrosterone(DHEA),DHEA sulfate,and aging:contribution of the DHEAge Study to a sociobiomedical issue.Proc Natl Acad Sci USA 2000;97:4279-4284[PMID:10760294]
151 Saru?M,Yüceyar H,Ayhan S,Türkel N,Tuzcuoglu I,Can M.The association of dehydroepiandrosterone,obesity,waist-hip ratio and insulin resistance with fatty liver in postmenopausal women--a hyperinsulinemic euglycemic insulin clamp study.Hepatogastroenterology 2003;50:771-774[PMID:12828082]
152 V?lzke H,Aumann N,Krebs A,Nauck M,Steveling A,Lerch MM,Rosskopf D,Wallaschofski H.Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men.Int J Androl 2010;33:45-53[PMID:19226405 DOI:10.1111/j.1365-2605.2009.00953.x]
153 Koehler E,Swain J,Sanderson S,Krishnan A,Watt K,Charlton M.Growth hormone,dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis:an endocrine signature for advanced fibrosis in obese patients.Liver Int 2012;32:279-286[PMID:22098614 DOI:10.1111/j.1478-3231.2011.02637.x]
154 Bahcecioglu IH,Yalniz M,Ilhan N,Ataseven H,Ozercan IH.Levels of serum vitamin A,alpha-tocopherol and malondialdehyde in patients with non-alcoholic steatohepatitis:relationship with histopathologic severity.Int J Clin Pract 2005;59:318-323[PMID:15857329 DOI:10.1111/j.1742-1241.2004.00312.x]
155 Osawa Y,Hoshi M,Yasuda I,Saibara T,Moriwaki H,Kozawa O.Tumor necrosis factor-αpromotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1production in hepatic stellate cells.PLo S One 2013;8:e65251[PMID:23755201 DOI:10.1371/journal.pone.0065251]
156 Wieckowska A,Mc Cullough AJ,Feldstein AE.Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis:present and future.Hepatology 2007;46:582-589[PMID:17661414 DOI:10.1002/hep.21768]
157 Romero FP.Will non-invasive testing replace liver biopsy in the diagnosis and follow-up of non-alcoholic steatohepatitis(NASH)?Rev Esp Enferm Dig 2009;101:521-527[PMID:19785490]
158 Wieckowska A,Feldstein AE.Diagnosis of nonalcoholic fatty liver disease:invasive versus noninvasive.Semin Liver Dis 2008;28:386-395[PMID:18956295 DOI:10.1055/s-0028-1091983]
2 Moore JB.Non-alcoholic fatty liver disease:the hepatic consequence of obesity and the metabolic syndrome.Proc Nutr Soc 2010;69:211-220[PMID:20158939 DOI:10.1017/S0029665110000030]
3 Paschos P,Paletas K.Non alcoholic fatty liver disease and metabolic syndrome.Hippokratia 2009;13:9-19[PMID:19240815]
4 Pulzi FB,Cisternas R,Melo MR,Ribeiro CM,Malheiros CA,Salles JE.New clinical score to diagnose nonalcoholic steatohepatitis in obese patients.Diabetol Metab Syndr 2011;3:3[PMID:21345221DOI:10.1186/1758-5996-3-3]
5 Collier J.Non-alcoholic fatty liver disease.Medicine 2007;35:86-88[DOI:10.1016/j.mpmed.2006.11.010]
6 Tevar AD,Clarke C,Wang J,Rudich SM,Woodle ES,Lentsch AB,Edwards ML.Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.J Am Coll Surg 2010;210:515-526[PMID:20347746 DOI:10.1016/j.jamcollsurg.2010.01.020]
7 Chitturi S,Farrell GC,Hashimoto E,Saibara T,Lau GK,Sollano JD.Non-alcoholic fatty liver disease in the Asia-Pacific region:definitions and overview of proposed guidelines.J Gastroenterol Hepatol 2007;22:778-787[PMID:17565630 DOI:10.1111/j.1440-1746.2007.05001.x]
8 Fan JG,Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China.J Hepatol 2009;50:204-210[PMID:19014878DOI:10.1016/j.jhep.2008.10.010]
9 Westerbacka J,Cornér A,Tiikkainen M,Tamminen M,Vehkavaara S,H?kkinen AM,Fredriksson J,Yki-J?rvinen H.Women and men have similar amounts of liver and intra-abdominal fat,despite more subcutaneous fat in women:implications for sex differences in markers of cardiovascular risk.Diabetologia 2004;47:1360-1369[PMID:15309287 DOI:10.1007/s00125-004-1460-1]
10 De Hewavisenthi SJ,Dassanayaka AS,De Silva HJ.Clinical,biochemical and histological characteristics of a Sri Lankan population of non-alcoholic steatohepatitis(NASH)patients.Ceylon Med J 2005;50:113-116[PMID:16252575]
11 Baranova A,Younossi ZM.The future is around the corner:Noninvasive diagnosis of progressive nonalcoholic steatohepatitis.Hepatology 2008;47:373-375[PMID:18220279 DOI:10.1002/hep.22140]
12 Poynard T,Ratziu V,Naveau S,Thabut D,Charlotte F,Messous D,Capron D,Abella A,Massard J,Ngo Y,Munteanu M,Mercadier A,Manns M,Albrecht J.The diagnostic value of biomarkers(Steato Test)for the prediction of liver steatosis.Comp Hepatol2005;4:10[PMID:16375767 DOI:10.1186/1476-5926-4-10]
13 Castera L.Non-invasive diagnosis of steatosis and fibrosis.Diabetes Metab 2008;34:674-679[PMID:19195629 DOI:10.1016/S1262-3636(08)74603-2]
14 Bondini S,Kleiner DE,Goodman ZD,Gramlich T,Younossi ZM.Pathologic assessment of non-alcoholic fatty liver disease.Clin Liver Dis 2007;11:17-23,vii[PMID:17544969 DOI:10.1016/j.cld.2007.02.002]
15 Ratziu V,Charlotte F,Heurtier A,Gombert S,Giral P,Bruckert E,Grimaldi A,Capron F,Poynard T.Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology 2005;128:1898-1906[PMID:15940625]
16 Manousou P,Kalambokis G,Grillo F,Watkins J,Xirouchakis E,Pleguezuelo M,Leandro G,Arvaniti V,Germani G,Patch D,Calvaruso V,Mikhailidis DP,Dhillon AP,Burroughs AK.Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.Liver Int 2011;31:730-739[PMID:21457446 DOI:10.1111/j.1478-3231.2011.02488.x]
17 Wilson S,Chalasani N.Noninvasive markers of advanced histology in nonalcoholic fatty liver disease:are we there yet?Gastroenterology 2007;133:1377-1378;discussion 1378-1379[PMID:17919509 DOI:10.1053/j.gastro.2007.08.045]
18 Díez-Vallejo J,Comas-Fuentes A.Asymptomatic hypertransaminasemia in patients in primary care.Rev Esp Enferm Dig 2011;103:530-535[PMID:22054268]
19 Hossain N,Afendy A,Stepanova M,Nader F,Srishord M,Rafiq N,Goodman Z,Younossi Z.Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol 2009;7:1224-1229,1229e1-e2[PMID:19559819 DOI:10.1016/j.cgh.2009.06.007]
20 Wilfred de Alwis NM,Day CP.Genetics of alcoholic liver disease and nonalcoholic fatty liver disease.Semin Liver Dis 2007;27:44-54[PMID:17295176 DOI:10.1055/s-2006-960170]
21 Ioannou GN,Boyko EJ,Lee SP.The prevalence and predictors of elevated serum aminotransferase activity in the United States in1999-2002.Am J Gastroenterol 2006;101:76-82[PMID:16405537DOI:10.1111/j.1572-0241.2005.00341.x]
22 Esteghamati A,Jamali A,Khalilzadeh O,Noshad S,Khalili M,Zandieh A,Morteza A,Nakhjavani M.Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.Diabetol Metab Syndr 2010;2:65[PMID:21047423DOI:10.1186/1758-5996-2-65]
23 Koga M,Saito H,Mukai M,Saibara T,Kasayama S.Serum dehydroepiandrosterone sulphate levels in patients with nonalcoholic fatty liver disease.Intern Med 2011;50:1657-1661[PMID:21841322]
24 Pourshams A,Malekzadeh R,Monavvari A,Akbari MR,Mohamadkhani A,Yarahmadi S,Seddighi N,Mohamadnejad M,Sotoudeh M,Madjlessi A.Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors.J Gastroenterol Hepatol 2005;20:229-233[PMID:15683425 DOI:10.1111/j.1440-1746.2004.03511.x]
25 Fracanzani AL,Valenti L,Bugianesi E,Andreoletti M,Colli A,Vanni E,Bertelli C,Fatta E,Bignamini D,Marchesini G,Fargion S.Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels:a role for insulin resistance and diabetes.Hepatology 2008;48:792-798[PMID:18752331 DOI:10.1002/hep.22429]
26 Neuschwander-Tetri BA,Clark JM,Bass NM,Van Natta ML,Unalp-Arida A,Tonascia J,Zein CO,Brunt EM,Kleiner DE,Mc Cullough AJ,Sanyal AJ,Diehl AM,Lavine JE,Chalasani N,Kowdley KV.Clinical,laboratory and histological associations in adults with nonalcoholic fatty liver disease.Hepatology 2010;52:913-924[PMID:20648476 DOI:10.1002/hep.23784]
27 Ratziu V,Giral P,Charlotte F,Bruckert E,Thibault V,Theodorou I,Khalil L,Turpin G,Opolon P,Poynard T.Liver fibrosis in overweight patients.Gastroenterology 2000;118:1117-1123[PMID:10833486]
28 Sumida Y,Yoneda M,Hyogo H,Itoh Y,Ono M,Fujii H,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Fujita K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T.Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.BMC Gastroenterol 2012;12:2[PMID:22221544 DOI:10.1186/1471-230X-12-2]
29 Ratziu V,Giral P,Munteanu M,Messous D,Mercadier A,Bernard M,Morra R,Imbert-Bismut F,Bruckert E,Poynard T.Screening for liver disease using non-invasive biomarkers(Fibro Test,Steato Test and Nash Test)in patients with hyperlipidaemia.Aliment Pharmacol Ther 2007;25:207-218[PMID:17229244 DOI:10.1111/j.1365-2036.2006.03182.x]
30 Calès P,Boursier J,Chaigneau J,LainéF,Sandrini J,Michalak S,Hubert I,Dib N,Oberti F,Bertrais S,Hunault G,Cavaro-Ménard C,Gallois Y,Deugnier Y,Rousselet MC.Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.Liver Int 2010;30:1346-1354[PMID:20666992 DOI:10.1111/j.1478-3231.2010.02314.x]
31 Browning JD.Statins and hepatic steatosis:perspectives from the Dallas Heart Study.Hepatology 2006;44:466-471[PMID:16871575 DOI:10.1002/hep.21248]
32 Bedogni G,Miglioli L,Masutti F,Tiribelli C,Marchesini G,Bellentani S.Prevalence of and risk factors for nonalcoholic fatty liver disease:the Dionysos nutrition and liver study.Hepatology2005;42:44-52[PMID:15895401 DOI:10.1002/hep.20734]
33 Browning JD,Szczepaniak LS,Dobbins R,Nuremberg P,Horton JD,Cohen JC,Grundy SM,Hobbs HH.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity.Hepatology 2004;40:1387-1395[PMID:15565570 DOI:10.1002/hep.20466]
34 Gholam PM,Flancbaum L,Machan JT,Charney DA,Kotler DP.Nonalcoholic fatty liver disease in severely obese subjects.Am JGastroenterol 2007;102:399-408[PMID:17311652 DOI:10.1111/j.1572-0241.2006.01041.x]
35 Chang Y,Ryu S,Sung E,Jang Y.Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease.Clin Chem 2007;53:686-692[PMID:17272484DOI:10.1373/clinchem.2006.081257]
36 Leite NC,Salles GF,Araujo AL,Villela-Nogueira CA,Cardoso CR.Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.Liver Int 2009;29:113-119[PMID:18384521 DOI:10.1111/j.1478-3231.2008.01718.x]
37 M’Kada H,Munteanu M,Perazzo H,Ngo Y,Ramanujam N,Imbert-Bismut F,Ratziu V,Bonnefont-Rousselot D,Souberbielle B,Schuppe-Koistinen I,Poynard T.What are the best reference values for a normal serum alanine transaminase activity(ALT)?Impact on the presumed prevalence of drug induced liver injury(DILI).Regul Toxicol Pharmacol 2011;60:290-295[PMID:21539883 DOI:10.1016/j.yrtph.2011.04.002]
38 Prati D,Taioli E,Zanella A,Della Torre E,Butelli S,Del Vecchio E,Vianello L,Zanuso F,Mozzi F,Milani S,Conte D,Colombo M,Sirchia G.Updated definitions of healthy ranges for serum alanine aminotransferase levels.Ann Intern Med 2002;137:1-10[PMID:12093239]
39 Miyake T,Kumagi T,Hirooka M,Koizumi M,Furukawa S,Ueda T,Tokumoto Y,Ikeda Y,Abe M,Kitai K,Hiasa Y,Matsuura B,Onji M.Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease:a community-based cross-sectional study.J Gastroenterol 2012;47:696-703[PMID:22331365 DOI:10.1007/s00535-012-0534-y]
40 Kaplan MM.Alanine aminotransferase levels:what’s normal?Ann Intern Med 2002;137:49-51[PMID:12093245 DOI:10.7326/0003-4819-137-1-200207020-00012]
41 Uslusoy HS,Nak SG,Gülten M,Biyikli Z.Non-alcoholic steatohepatitis with normal aminotransferase values.World JGastroenterol 2009;15:1863-1868[PMID:19370784 DOI:10.3748/wjg.15.1863]
42 Kayadibi H,Gültepe M,Yasar B,Ince AT,Ozcan O,Ipcioglu OM,Kurdas OO,Bolat B,Benek YZ,Guveli H,Atalay S,Ozkara S,Keskin O.Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease:a surrogate marker to distinguish steatohepatitis from simple steatosis.Dig Dis Sci 2009;54:1764-1771[PMID:18989777 DOI:10.1007/s10620-008-0535-0]
43 Riquelme A,Arrese M,Soza A,Morales A,Baudrand R,PérezAyuso RM,González R,Alvarez M,Hernández V,García-Zattera MJ,Otarola F,Medina B,Rigotti A,Miquel JF,Marshall G,Nervi F.Non-alcoholic fatty liver disease and its association with obesity,insulin resistance and increased serum levels of C-reactive protein in Hispanics.Liver Int 2009;29:82-88[PMID:18647235 DOI:10.1111/j.1478-3231.2008.01823.x]
44 Shi JP,Xun YH,Hu CB,Zhang L,Liu H,Lou GQ,Fan JG.Clinical and histological features of non-alcoholic fatty liver disease.Zhonghua Ganzangbing Zazhi 2009;17:812-816[PMID:19958638]
45 Prashanth M,Ganesh HK,Vima MV,John M,Bandgar T,Joshi SR,Shah SR,Rathi PM,Joshi AS,Thakkar H,Menon PS,Shah NS.Prevalence of nonalcoholic fatty liver disease in patients with type2 diabetes mellitus.J Assoc Physicians India 2009;57:205-210[PMID:19588648]
46 Kashyap SR,Diab DL,Baker AR,Yerian L,Bajaj H,GrayMc Guire C,Schauer PR,Gupta M,Feldstein AE,Hazen SL,Stein CM.Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.Obesity(Silver Spring)2009;17:1696-1701[PMID:19360015 DOI:10.1038/oby.2009.89]
47 Charatcharoenwitthaya P,Lindor KD,Angulo P.The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease.Dig Dis Sci 2012;57:1925-1931[PMID:22373863DOI:10.1007/s10620-012-2098-3]
48 Kaneda H,Hashimoto E,Yatsuji S,Tokushige K,Shiratori K.Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2006;21:1459-1465[PMID:16911693 DOI:10.1111/j.1440-1746.2006.04447.x]
49 Hsieh MH,Ho CK,Hou NJ,Hsieh MY,Lin WY,Yang JF,Chiu CC,Huang JF,Chang NC,Wang CL,Dai CY,Chuang WL,Yu ML.Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C.Int J Obes(Lond)2009;33:1309-1317[PMID:19752878DOI:10.1038/ijo.2009.172]
50 Fan JG,Saibara T,Chitturi S,Kim BI,Sung JJ,Chutaputti A.What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?J Gastroenterol Hepatol 2007;22:794-800[PMID:17498218 DOI:10.1111/j.1440-1746.2007.04952.x]
51 Munteanu M,Ratziu V,Morra R,Messous D,Imbert-Bismut F,Poynard T.Noninvasive biomarkers for the screening of fibrosis,steatosis and steatohepatitis in patients with metabolic risk factors:Fibro Test-Fibro Max experience.J Gastrointestin Liver Dis 2008;17:187-191[PMID:18568141]
52 Poynard T,Ratziu V,Charlotte F,Messous D,Munteanu M,ImbertBismut F,Massard J,Bonyhay L,Tahiri M,Thabut D,Cadranel JF,Le Bail B,de Ledinghen V.Diagnostic value of biochemical markers(Nash Test)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol2006;6:34[PMID:17096854 DOI:10.1186/1471-230X-6-34]
53 Angulo P,Hui JM,Marchesini G,Bugianesi E,George J,Farrell GC,Enders F,Saksena S,Burt AD,Bida JP,Lindor K,Sanderson SO,Lenzi M,Adams LA,Kench J,Therneau TM,Day CP.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology 2007;45:846-854[PMID:17393509 DOI:10.1002/hep.21496]
54 Wong VW,Wong GL,Chim AM,Tse AM,Tsang SW,Hui AY,Choi PC,Chan AW,So WY,Chan FK,Sung JJ,Chan HL.Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.Am J Gastroenterol 2008;103:1682-1688[PMID:18616651 DOI:10.1111/j.1572-0241.2008.01933.x]
55 Calès P,LainéF,Boursier J,Deugnier Y,Moal V,Oberti F,Hunault G,Rousselet MC,Hubert I,Laafi J,Ducluzeaux PH,Lunel F.Comparison of blood tests for liver fibrosis specific or not to NAFLD.J Hepatol 2009;50:165-173[PMID:18977552 DOI:10.1016/j.jhep.2008.07.035]
56 Younossi ZM,Page S,Rafiq N,Birerdinc A,Stepanova M,Hossain N,Afendy A,Younoszai Z,Goodman Z,Baranova A.A biomarker panel for non-alcoholic steatohepatitis(NASH)and NASH-related fibrosis.Obes Surg 2011;21:431-439[PMID:20532833 DOI:10.1007/s11695-010-0204-1]
57 Palekar NA,Naus R,Larson SP,Ward J,Harrison SA.Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.Liver Int 2006;26:151-156[PMID:16448452 DOI:10.1111/j.1478-3231.2005.01209.x]
58 Harrison SA,Oliver D,Arnold HL,Gogia S,NeuschwanderTetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut 2008;57:1441-1447[PMID:18390575 DOI:10.1136/gut.2007.146019]
59 Kruger FC,Daniels CR,Kidd M,Swart G,Brundyn K,van Rensburg C,Kotze M.APRI:a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.S Afr Med J 2011;101:477-480[PMID:21920102]
60 Yoshida M.Novel role of NPC1L1 in the regulation of hepatic metabolism:potential contribution of ezetimibe in NAFLD/NASHtreatment.Curr Vasc Pharmacol 2011;9:121-123[PMID:21044016]
61 Rafiq N,Bai C,Fang Y,Srishord M,Mc Cullough A,Gramlich T,Younossi ZM.Long-term follow-up of patients with nonalcoholic fatty liver.Clin Gastroenterol Hepatol 2009;7:234-238[PMID:19049831 DOI:10.1016/j.cgh.2008.11.005]
62 Fierbinteanu-Braticevici C,Baicus C,Tribus L,Papacocea R.Predictive factors for nonalcoholic steatohepatitis(NASH)in patients with nonalcoholic fatty liver disease(NAFLD).JGastrointestin Liver Dis 2011;20:153-159[PMID:21725512]
63 Younossi ZM,Gramlich T,Matteoni CA,Boparai N,Mc Cullough AJ.Nonalcoholic fatty liver disease in patients with type 2 diabetes.Clin Gastroenterol Hepatol 2004;2:262-265[PMID:15017611]
64 Suzuki A,Angulo P,Lymp J,Li D,Satomura S,Lindor K.Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.Liver Int 2005;25:779-786[PMID:15998429 DOI:10.1111/j.1478-3231.2005.01064.x]
65 Sumida Y,Yonei Y,Kanemasa K,Hara T,Inada Y,Sakai K,Imai S,Hibino S,Yamaguchi K,Mitsuyoshi H,Yasui K,Minami M,Itoh Y,Naito Y,Yoshikawa T,Okanoue T.Lower circulating levels of dehydroepiandrosterone,independent of insulin resistance,is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients.Hepatol Res 2010;40:901-910[PMID:20887595 DOI:10.1111/j.1872-034X.2010.00704.x]
66 Mawatari H,Yoneda M,Kirikoshi H,Maeda S,Nakajima A,Saito S.Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease.J Gastroenterol 2012;47:606-607;author reply 608[PMID:22388885]
67 Yoneda M,Fujii H,Sumida Y,Hyogo H,Itoh Y,Ono M,Eguchi Y,Suzuki Y,Aoki N,Kanemasa K,Imajo K,Chayama K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Yoshikawa T,Okanoue T.Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.J Gastroenterol 2011;46:1300-1306[PMID:21750883DOI:10.1007/s00535-011-0436-4]
68 Celikbilek M,Gürsoy S,Deniz K,Karaman A,Zararsiz G,Yurci A.Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease.Platelets 2013;24:194-199[PMID:22646469 DOI:10.3109/09537104.2012.688898]
69 Ozhan H,Aydin M,Yazici M,Yazgan O,Basar C,Gungor A,Onder E.Mean platelet volume in patients with non-alcoholic fatty liver disease.Platelets 2010;21:29-32[PMID:19947902 DOI:10.3109/09537100903391023]
70 Shin WY,Jung DH,Shim JY,Lee HR.The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population.Platelets 2011;22:442-446[PMID:21751850 DOI:10.3109/09537104.2010.540049]
71 Kilciler G,Genc H,Tapan S,Ors F,Kara M,Karadurmus N,Ercin CN,Karslioglu Y,Kilic S,Bagci S,Erbil MK,Dogru T.Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease.Ups J Med Sci 2010;115:253-259[PMID:20731535 DOI:10.3109/03009734.2010.500062]
72 Hashimoto E,Farrell GC.Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?J Gastroenterol Hepatol 2009;24:501-503[PMID:19368628 DOI:10.1111/j.1440-1746.2009.05806.x]
73 Siebler J,Galle PR,Weber MM.The gut-liver-axis:endotoxemia,inflammation,insulin resistance and NASH.J Hepatol 2008;48:1032-1034[PMID:18468548 DOI:10.1016/j.jhep.2008.03.007]
74 Kogiso T,Moriyoshi Y,Shimizu S,Nagahara H,Shiratori K.Highsensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population.J Gastroenterol 2009;44:313-321[PMID:19271113 DOI:10.1007/s00535-009-0002-5]
75 Kerner A,Avizohar O,Sella R,Bartha P,Zinder O,Markiewicz W,Levy Y,Brook GJ,Aronson D.Association between elevated liver enzymes and C-reactive protein:possible hepatic contribution to systemic inflammation in the metabolic syndrome.Arterioscler Thromb Vasc Biol 2005;25:193-197[PMID:15499043 DOI:10.1161/01.ATV.0000148324.63685.6a]
76 Yoneda M,Mawatari H,Fujita K,Iida H,Yonemitsu K,Kato S,Takahashi H,Kirikoshi H,Inamori M,Nozaki Y,Abe Y,Kubota K,Saito S,Iwasaki T,Terauchi Y,Togo S,Maeyama S,Nakajima A.High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis(NASH)and also of the severity of fibrosis in NASH.J Gastroenterol 2007;42:573-582[PMID:17653654 DOI:10.1007/s00535-007-2060-x]
77 Uchihara M,Izumi N.[High-sensitivity C-reactive protein(hsCRP):a promising biomarker for the screening of non-alcoholic steatohepatitis(NASH)].Nihon Rinsho 2006;64:1133-1138[PMID:16768121]
78 Zimmermann E,Anty R,Tordjman J,Verrijken A,Gual P,Tran A,Iannelli A,Gugenheim J,Bedossa P,Francque S,Le MarchandBrustel Y,Clement K,Van Gaal L,S?rensen TI,Jess T.C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.J Hepatol 2011;55:660-665[PMID:21238518 DOI:10.1016/j.jhep.2010.12.017]
79 Park SH,Kim BI,Yun JW,Kim JW,Park DI,Cho YK,Sung IK,Park CY,Sohn CI,Jeon WK,Kim H,Rhee EJ,Lee WY,Kim SW.Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.JGastroenterol Hepatol 2004;19:694-698[PMID:15151626 DOI:10.1111/j.1440-1746.2004.03362.x]
80 Anty R,Bekri S,Luciani N,Saint-Paul MC,Dahman M,Iannelli A,Amor IB,Staccini-Myx A,Huet PM,Gugenheim J,Sadoul JL,Le Marchand-Brustel Y,Tran A,Gual P.The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome,Type 2diabetes,and NASH.Am J Gastroenterol 2006;101:1824-1833[PMID:16790033 DOI:10.1111/j.1572-0241.2006.00724.x]
81 Park HS,Park JY,Yu R.Relationship of obesity and visceral adiposity with serum concentrations of CRP,TNF-alpha and IL-6.Diabetes Res Clin Pract 2005;69:29-35[PMID:15955385 DOI:10.1016/j.diabres.2004.11.007]
82 Sivapackianathan R,Asivatham AJ,Al-Mahtab M,Chowdhury TA.Association between non-alcoholic fatty liver disease and metabolic syndrome.Int J Hepatol 2010;1:17-24
83 Khera A,Vega GL,Das SR,Ayers C,Mc Guire DK,Grundy SM,de Lemos JA.Sex differences in the relationship between C-reactive protein and body fat.J Clin Endocrinol Metab 2009;94:3251-3258[PMID:19567538 DOI:10.1210/jc.2008-2406]
84 Lakoski SG,Cushman M,Criqui M,Rundek T,Blumenthal RS,D’Agostino RB,Herrington DM.Gender and C-reactive protein:data from the Multiethnic Study of Atherosclerosis(MESA)cohort.Am Heart J 2006;152:593-598[PMID:16923436 DOI:10.1016/j.ahj.2006.02.015]
85 Khera A,Mc Guire DK,Murphy SA,Stanek HG,Das SR,Vongpatanasin W,Wians FH,Grundy SM,de Lemos JA.Race and gender differences in C-reactive protein levels.J Am Coll Cardiol 2005;46:464-469[PMID:16053959 DOI:10.1016/j.jacc.2005.04.051]
86 Das I.Raised C-reactive protein levels in serum from smokers.Clin Chim Acta 1985;153:9-13[PMID:2416495]
87 Tsochatzis EA,Papatheodoridis GV,Archimandritis AJ.Adipokines in nonalcoholic steatohepatitis:from pathogenesis to implications in diagnosis and therapy.Mediators Inflamm 2009;2009:831670[PMID:19753129 DOI:10.1155/2009/831670]
88 Oda E,Watanabe K.High-sensitivity C-reactive protein and metabolic syndrome(insulin resistance syndrome),including nonalcoholic steatohepatitis.J Gastroenterol 2008;43:312-313;author reply 313[PMID:18458848 DOI:10.1007/s00535-008-2175-8]
89 Kowdley KV,Belt P,Wilson LA,Yeh MM,NeuschwanderTetri BA,Chalasani N,Sanyal AJ,Nelson JE.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.Hepatology 2012;55:77-85[PMID:21953442 DOI:10.1002/hep.24706]
90 Oh MK,Winn J,Poordad F.Review article:diagnosis and treatment of non-alcoholic fatty liver disease.Aliment Pharmacol Ther 2008;28:503-522[PMID:18532991 DOI:10.1111/j.1365-2036.2008.03752.x]
91 Sumida Y,Yoneda M,Hyogo H,Yamaguchi K,Ono M,Fujii H,Eguchi Y,Suzuki Y,Imai S,Kanemasa K,Fujita K,Chayama K,Yasui K,Saibara T,Kawada N,Fujimoto K,Kohgo Y,Okanoue T.A simple clinical scoring system using ferritin,fasting insulin,and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.J Gastroenterol 2011;46:257-268[PMID:20842510 DOI:10.1007/s00535-010-0305-6]
92 Polyzos SA,Kountouras J,Patsiaoura K,Katsiki E,Zafeiriadou E,Deretzi G,Zavos C,Gavalas E,Katsinelos P,Mane V,Slavakis A.Serum homocysteine levels in patients with nonalcoholic fatty liver disease.Ann Hepatol 2012;11:68-76[PMID:22166563]
93 Blendis L,Oren R,Halpern Z.NASH:Can we iron out the pathogenesis?Gastroenterology 2000;118:981-983[PMID:10784602 DOI:10.1016/S0016-5085(00)70189-2]
94 Yoneda M,Mawatari H,Fujita K,Yonemitsu K,Kato S,Takahashi H,Kirikoshi H,Inamori M,Nozaki Y,Abe Y,Kubota K,Saito S,Iwasaki T,Terauchi Y,Togo S,Maeyama S,Nakajima A.Type IVcollagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.J Gastroenterol 2007;42:375-381[PMID:17530362 DOI:10.1007/s00535-007-2014-3]
95 Yoneda M,Uchiyama T,Kato S,Endo H,Fujita K,Yoneda K,Mawatari H,Iida H,Takahashi H,Kirikoshi H,Inamori M,Nozaki Y,Kobayashi N,Kubota K,Saito S,Maeyama S,Sagara M,Aburatani H,Kodama T,Nakajima A.Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis(NASH).BMC Gastroenterol 2008;8:53[PMID:19014569 DOI:10.1186/1471-230X-8-53]
96 Polyzos SA,Kountouras J,Zavos C.Nonalcoholic fatty liver disease:the pathogenetic roles of insulin resistance and adipocytokines.Curr Mol Med 2009;9:299-314[PMID:19355912]
97 Yalniz M,Bahcecioglu IH,Ataseven H,Ustundag B,Ilhan F,Poyrazoglu OK,Erensoy A.Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis.Mediators Inflamm 2006;2006:34295[PMID:17392582 DOI:10.1155/MI/2006/34295]
98 Jarrar MH,Baranova A,Collantes R,Ranard B,Stepanova M,Bennett C,Fang Y,Elariny H,Goodman Z,Chandhoke V,Younossi ZM.Adipokines and cytokines in non-alcoholic fatty liver disease.Aliment Pharmacol Ther 2008;27:412-421[PMID:18081738DOI:10.1111/j.1365-2036.2007.03586.x]
99 Tilg H.The role of cytokines in non-alcoholic fatty liver disease.Dig Dis 2010;28:179-185[PMID:20460908 DOI:10.1159/000282083]
100 Hui JM,Hodge A,Farrell GC,Kench JG,Kriketos A,George J.Beyond insulin resistance in NASH:TNF-alpha or adiponectin?Hepatology 2004;40:46-54[PMID:15239085 DOI:10.1002/hep.20280]
101 Buechler C,Wanninger J,Neumeier M.Adiponectin,a key adipokine in obesity related liver diseases.World J Gastroenterol2011;17:2801-2811[PMID:21734787 DOI:10.3748/wjg.v17.i23.2801]
102 Aller R,de Luis DA,Fernandez L,Calle F,Velayos B,Olcoz JL,Izaola O,Sagrado MG,Conde R,Gonzalez JM.Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease.Dig Dis Sci 2008;53:1088-1092[PMID:17934820 DOI:10.1007/s10620-007-9981-3]
103 Musso G,Gambino R,Durazzo M,Biroli G,Carello M,FagàE,Pacini G,De Michieli F,Rabbione L,Premoli A,Cassader M,Pagano G.Adipokines in NASH:postprandial lipid metabolism as a link between adiponectin and liver disease.Hepatology 2005;42:1175-1183[PMID:16231364 DOI:10.1002/hep.20896]
104 Shimada M,Kawahara H,Ozaki K,Fukura M,Yano H,Tsuchishima M,Tsutsumi M,Takase S.Usefulness of a combined evaluation of the serum adiponectin level,HOMA-IR,and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.Am J Gastroenterol 2007;102:1931-1938[PMID:17511754 DOI:10.1111/j.1572-0241.2007.01322.x]
105 Tokushige K,Hashimoto E,Noto H,Yatsuji S,Taniai M,Torii N,Shiratori K.Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease.JGastroenterol 2009;44:976-982[PMID:19484180 DOI:10.1007/s00535-009-0085-z]
106 Kaser S,Moschen A,Cayon A,Kaser A,Crespo J,Pons-Romero F,Ebenbichler CF,Patsch JR,Tilg H.Adiponectin and its receptors in non-alcoholic steatohepatitis.Gut 2005;54:117-121[PMID:15591515 DOI:10.1136/gut.2003.037010]
107 Younossi ZM,Jarrar M,Nugent C,Randhawa M,Afendy M,Stepanova M,Rafiq N,Goodman Z,Chandhoke V,Baranova A.Anovel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis(NASH).Obes Surg 2008;18:1430-1437[PMID:18500507 DOI:10.1007/s11695-008-9506-y]
108 Bethanis SK,Theocharis SE.Leptin in the field of hepatic fibrosis:a pivotal or an incidental player?Dig Dis Sci 2006;51:1685-1696[PMID:16958000 DOI:10.1007/s10620-006-9126-0]
109 Uygun A,Kadayifci A,Yesilova Z,Erdil A,Yaman H,Saka M,Deveci MS,Bagci S,Gulsen M,Karaeren N,Dagalp K.Serum leptin levels in patients with nonalcoholic steatohepatitis.Am J Gastroenterol 2000;95:3584-3589[PMID:11151896 DOI:10.1111/j.1572-0241.2000.03297.x]
110 Polyzos SA,Kountouras J,Zavos C,Deretzi G.The potential adverse role of leptin resistance in nonalcoholic fatty liver disease:a hypothesis based on critical review of the literature.J Clin Gastroenterol 2011;45:50-54[PMID:20717042 DOI:10.1097/MCG.0b013e3181ec5c66]
111 Chan JL,Wong SL,Mantzoros CS.Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states:regulation by gender and adiposity.Clin Pharmacokinet 2008;47:753-764[PMID:18840030 DOI:10.2165/00003088-200847110-00006]
112 Lo KM,Zhang J,Sun Y,Morelli B,Lan Y,Lauder S,Brunkhorst B,Webster G,Hallakou-Bozec S,DoaréL,Gillies SD.Engineering a pharmacologically superior form of leptin for the treatment of obesity.Protein Eng Des Sel 2005;18:1-10[PMID:15790575DOI:10.1093/protein/gzh102]
113 Zelissen PM,Stenlof K,Lean ME,Fogteloo J,Keulen ET,Wilding J,Finer N,R?ssner S,Lawrence E,Fletcher C,Mc Camish M.Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults:a randomized,placebo-controlled trial.Diabetes Obes Metab 2005;7:755-761[PMID:16219020DOI:10.1111/j.1463-1326.2005.00468.x]
114 Chitturi S,Farrell G,Frost L,Kriketos A,Lin R,Fung C,Liddle C,Samarasinghe D,George J.Serum leptin in NASH correlates with hepatic steatosis but not fibrosis:a manifestation of lipotoxicity?Hepatology 2002;36:403-409[PMID:12143049 DOI:10.1053/jhep.2002.34738]
115 Mantzoros CS,Moschos S,Avramopoulos I,Kaklamani V,Liolios A,Doulgerakis DE,Griveas I,Katsilambros N,Flier JS.Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans.J Clin Endocrinol Metab 1997;82:3408-3413[PMID:9329377 DOI:10.1210/jcem.82.10.4323]
116 Nakao K,Nakata K,Ohtsubo N,Maeda M,Moriuchi T,Ichikawa T,Hamasaki K,Kato Y,Eguchi K,Yukawa K,Ishii N.Association between nonalcoholic fatty liver,markers of obesity,and serum leptin level in young adults.Am J Gastroenterol 2002;97:1796-1801[PMID:12135038 DOI:10.1111/j.1572-0241.2002.05846.x]
117 Canbakan B,Tahan V,Balci H,Hatemi I,Erer B,Ozbay G,Sut N,Hacibekiroglu M,Imeryuz N,Senturk H.Leptin in nonalcoholic fatty liver disease.Ann Hepatol 2008;7:249-254[PMID:18753993]
118 Serin E,Ozer B,GümürdülüY,Kayasel?uk F,Kul K,Boyacio?lu S.Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver.J Gastroenterol 2003;38:471-476[PMID:12768390 DOI:10.1007/s00535-002-1084-5]
119 Procaccini C,Galgani M,De Rosa V,Carbone F,La Rocca C,Ranucci G,Iorio R,Matarese G.Leptin:the prototypic adipocytokine and its role in NAFLD.Curr Pharm Des 2010;16:1902-1912[PMID:20370676]
120 Torres DM,Harrison SA.Diagnosis and therapy of nonalcoholic steatohepatitis.Gastroenterology 2008;134:1682-1698[PMID:18471547 DOI:10.1053/j.gastro.2008.02.077]
121 Lydatakis H,Hager IP,Kostadelou E,Mpousmpoulas S,Pappas S,Diamantis I.Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.Liver Int 2006;26:864-871[PMID:16911470 DOI:10.1111/j.1478-3231.2006.01312.x]
122 Fon Tacer K,Kuzman D,Seliskar M,Pompon D,Rozman D.TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes.Physiol Genomics 2007;31:216-227[PMID:17566076 DOI:10.1152/physiolgenomics.00264.2006]
123 Feingold KR,Soued M,Serio MK,Adi S,Moser AH,Grunfeld C.The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis.Metabolism 1990;39:623-632[PMID:2352479]
124 Das SK,Balakrishnan V.Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease.Indian J Clin Biochem 2011;26:202-209[PMID:22468051 DOI:10.1007/s12291-011-0121-7]
125 Aigner E,Theurl I,Theurl M,Lederer D,Haufe H,Dietze O,Strasser M,Datz C,Weiss G.Pathways underlying iron accumulation in human nonalcoholic fatty liver disease.Am J Clin Nutr 2008;87:1374-1383[PMID:18469261]
126 Bahcecioglu IH,Yalniz M,Ataseven H,Ilhan N,Ozercan IH,Seckin D,Sahin K.Levels of serum hyaluronic acid,TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.Hepatogastroenterology 2005;52:1549-1553[PMID:16201116]
127 Lebensztejn DM,Kowalczuk D,Tarasów E,Skiba E,Kaczmarski M.Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD.Adv Med Sci 2010;55:74-79[PMID:20371430 DOI:10.2478/v10039-010-0008-5]
128 Kugelmas M,Hill DB,Vivian B,Marsano L,Mc Clain CJ.Cytokines and NASH:a pilot study of the effects of lifestyle modification and vitamin E.Hepatology 2003;38:413-419[PMID:12883485 DOI:10.1053/jhep.2003.50]
129 Ferreira VS,Pernambuco RB,Lopes EP,Morais CN,Rodrigues MC,Arruda MJ,Silva LM,Vilar L.Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.Arq Bras Endocrinol Metabol 2010;54:362-368[PMID:20625647 DOI:10.1590/S0004-27302010000400004]
130 Hui JM,Farrell GC,Kench JG,George J.High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD.Hepatology 2004;39:1458-1459[PMID:15122781 DOI:10.1002/hep.20223]
131 Zamora-Valdés D,Méndez-Sánchez N.Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis.Ann Hepatol 2007;6:281-283[PMID:18007563]
132 Abiru S,Migita K,Maeda Y,Daikoku M,Ito M,Ohata K,Nagaoka S,Matsumoto T,Takii Y,Kusumoto K,Nakamura M,Komori A,Yano K,Yatsuhashi H,Eguchi K,Ishibashi H.Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis.Liver Int 2006;26:39-45[PMID:16420507 DOI:10.1111/j.1478-3231.2005.01191.x]
133 Yilmaz Y,Kedrah AE,Ozdogan O.Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.World J Gastroenterol 2009;15:4387-4391[PMID:19764089 DOI:10.3748/wjg.15.4387]
134 Wieckowska A,Zein NN,Yerian LM,Lopez AR,Mc Cullough AJ,Feldstein AE.In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.Hepatology 2006;44:27-33[PMID:16799979 DOI:10.1002/hep.21223]
135 Ulukaya E,Yilmaztepe A,Akgoz S,Linder S,Karadag M.The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.Lung Cancer 2007;56:399-404[PMID:17316892 DOI:10.1016/j.lungcan.2007.01.015]
136 Tarantino G,Conca P,Coppola A,Vecchione R,Di Minno G.Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis.Eur JClin Invest 2007;37:48-53[PMID:17181567 DOI:10.1111/j.1365-2362.2007.01745.x]
137 Wieckowska A,Lopez AR,Zein NN,Mc Cullough AJ,Feldstein AE.Noninvasive assessment of hepatocyte apoptosis in nonalcoholic fatty liver disease;a multi-center validation study.Gastroenterology 2007;132:A729[DOI:10.1002/hep.23050]
138 Diab DL,Yerian L,Schauer P,Kashyap SR,Lopez R,Hazen SL,Feldstein AE.Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.Clin Gastroenterol Hepatol 2008;6:1249-1254[PMID:18995215 DOI:10.1016/j.cgh.2008.07.016]
139 Musso G,Gambino R,Cassader M,Pagano G.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity.Ann Med 2011;43:617-649[PMID:21039302 DOI:10.3109/07853890.2010.518623]
140 Malik R,Chang M,Bhaskar K,Nasser I,Curry M,Schuppan D,Byrnes V,Afdhal N.The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.J Gastroenterol Hepatol 2009;24:564-568[PMID:19378390]
141 Rosenberg WM,Voelker M,Thiel R,Becka M,Burt A,Schuppan D,Hubscher S,Roskams T,Pinzani M,Arthur MJ.Serum markers detect the presence of liver fibrosis:a cohort study.Gastroenterology 2004;127:1704-1713[PMID:15578508]
142 Feldstein AE,Wieckowska A,Lopez AR,Liu YC,Zein NN,Mc Cullough AJ.Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis:a multicenter validation study.Hepatology 2009;50:1072-1078[PMID:19585618]
143 Sakugawa H,Nakayoshi T,Kobashigawa K,Yamashiro T,Maeshiro T,Miyagi S,Shiroma J,Toyama A,Nakayoshi T,Kinjo F,Saito A.Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.World JGastroenterol 2005;11:255-259[PMID:15633226]
144 Santos VN,Leite-Mór MM,Kondo M,Martins JR,Nader H,Lanzoni VP,Parise ER.Serum laminin,type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease.Braz J Med Biol Res 2005;38:747-753[PMID:15917956]
145 Miele L,Forgione A,La Torre G,Vero V,Cefalo C,Racco S,Vellone VG,Vecchio FM,Gasbarrini G,Rapaccini GL,Neuman MG,Grieco A.Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.Transl Res 2009;154:194-201[PMID:19766963 DOI:10.1016/j.trsl.2009.06.007]
146 Preiss D,Sattar N.Non-alcoholic fatty liver disease:an overview of prevalence,diagnosis,pathogenesis and treatment considerations.Clin Sci(Lond)2008;115:141-150[PMID:18662168 DOI:10.1042/CS20070402]
147 Dowman JK,Tomlinson JW,Newsome PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis.Aliment Pharmacol Ther 2011;33:525-540[PMID:21198708 DOI:10.1111/j.1365-2036.2010.04556.x]
148 Lesmana CR,Hasan I,Budihusodo U,Gani RA,Krisnuhoni E,Akbar N,Lesmana LA.Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis.J Dig Dis 2009;10:201-206[PMID:19659788DOI:10.1111/j.1751-2980.2009.00386.x]
149 Charlton M,Angulo P,Chalasani N,Merriman R,Viker K,Charatcharoenwitthaya P,Sanderson S,Gawrieh S,Krishnan A,Lindor K.Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.Hepatology2008;47:484-492[PMID:18220286 DOI:10.1002/hep.22063]
150 Baulieu EE,Thomas G,Legrain S,Lahlou N,Roger M,Debuire B,Faucounau V,Girard L,Hervy MP,Latour F,Leaud MC,Mokrane A,Pitti-Ferrandi H,Trivalle C,de Lacharrière O,Nouveau S,RakotoArison B,Souberbielle JC,Raison J,Le Bouc Y,Raynaud A,Girerd X,Forette F.Dehydroepiandrosterone(DHEA),DHEA sulfate,and aging:contribution of the DHEAge Study to a sociobiomedical issue.Proc Natl Acad Sci USA 2000;97:4279-4284[PMID:10760294]
151 Saru?M,Yüceyar H,Ayhan S,Türkel N,Tuzcuoglu I,Can M.The association of dehydroepiandrosterone,obesity,waist-hip ratio and insulin resistance with fatty liver in postmenopausal women--a hyperinsulinemic euglycemic insulin clamp study.Hepatogastroenterology 2003;50:771-774[PMID:12828082]
152 V?lzke H,Aumann N,Krebs A,Nauck M,Steveling A,Lerch MM,Rosskopf D,Wallaschofski H.Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men.Int J Androl 2010;33:45-53[PMID:19226405 DOI:10.1111/j.1365-2605.2009.00953.x]
153 Koehler E,Swain J,Sanderson S,Krishnan A,Watt K,Charlton M.Growth hormone,dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis:an endocrine signature for advanced fibrosis in obese patients.Liver Int 2012;32:279-286[PMID:22098614 DOI:10.1111/j.1478-3231.2011.02637.x]
154 Bahcecioglu IH,Yalniz M,Ilhan N,Ataseven H,Ozercan IH.Levels of serum vitamin A,alpha-tocopherol and malondialdehyde in patients with non-alcoholic steatohepatitis:relationship with histopathologic severity.Int J Clin Pract 2005;59:318-323[PMID:15857329 DOI:10.1111/j.1742-1241.2004.00312.x]
155 Osawa Y,Hoshi M,Yasuda I,Saibara T,Moriwaki H,Kozawa O.Tumor necrosis factor-αpromotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1production in hepatic stellate cells.PLo S One 2013;8:e65251[PMID:23755201 DOI:10.1371/journal.pone.0065251]
156 Wieckowska A,Mc Cullough AJ,Feldstein AE.Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis:present and future.Hepatology 2007;46:582-589[PMID:17661414 DOI:10.1002/hep.21768]
157 Romero FP.Will non-invasive testing replace liver biopsy in the diagnosis and follow-up of non-alcoholic steatohepatitis(NASH)?Rev Esp Enferm Dig 2009;101:521-527[PMID:19785490]
158 Wieckowska A,Feldstein AE.Diagnosis of nonalcoholic fatty liver disease:invasive versus noninvasive.Semin Liver Dis 2008;28:386-395[PMID:18956295 DOI:10.1055/s-0028-1091983]